AILT
MCID: ANG046
MIFTS: 52

Angioimmunoblastic T-Cell Lymphoma (AILT)

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Angioimmunoblastic T-Cell Lymphoma

MalaCards integrated aliases for Angioimmunoblastic T-Cell Lymphoma:

Name: Angioimmunoblastic T-Cell Lymphoma 12 52 58 54 15 17 32
Immunoblastic Lymphadenopathy 52 58 43 17
T-Cell Lymphoma, Aild Type 52 58
Lymphogranulomatosis X 52 58
Angioimmunoblastic Lymphadenopathy 71
Aitl 52
Ailt 58

Characteristics:

Orphanet epidemiological data:

58
angioimmunoblastic t-cell lymphoma
Age of onset: Adult;

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:0111147
MeSH 43 D007119
NCIt 49 C7528
SNOMED-CT 67 52097008
ICD10 32 C86.5
ICD10 via Orphanet 33 C86.5
UMLS via Orphanet 72 C0020981
Orphanet 58 ORPHA86886
UMLS 71 C0020981

Summaries for Angioimmunoblastic T-Cell Lymphoma

Disease Ontology : 12 A peripheral T-cell lymphoma characterized by autoimmune features and poor prognosis.

MalaCards based summary : Angioimmunoblastic T-Cell Lymphoma, also known as immunoblastic lymphadenopathy, is related to peripheral t-cell lymphoma and lymphoma, hodgkin, classic, and has symptoms including exanthema An important gene associated with Angioimmunoblastic T-Cell Lymphoma is CXCL13 (C-X-C Motif Chemokine Ligand 13), and among its related pathways/superpathways are Innate Immune System and Class I MHC mediated antigen processing and presentation. The drugs Pirarubicin and asparaginase have been mentioned in the context of this disorder. Affiliated tissues include t cells, b cells and bone, and related phenotypes are hematopoietic system and immune system

Wikipedia : 74 Angioimmunoblastic T-cell lymphoma (AITL, sometimes misspelled AILT) (formerly known as... more...

Related Diseases for Angioimmunoblastic T-Cell Lymphoma

Diseases related to Angioimmunoblastic T-Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 285)
# Related Disease Score Top Affiliating Genes
1 peripheral t-cell lymphoma 31.9 TNFRSF8 TIA1 TET2 SYK RHOA PDCD1
2 lymphoma, hodgkin, classic 31.4 TNFRSF8 TIA1 GZMB BCL6
3 b-cell lymphoma 31.3 TNFRSF8 TIA1 SYK MME CXCL13 BCL6
4 lymphoma 31.2 TNFRSF8 TIA1 RHOA PDCD1 MME ITK
5 marginal zone b-cell lymphoma 31.2 TNFRSF8 MME BCL6
6 anaplastic large cell lymphoma 31.2 TNFRSF8 TIA1 GZMB
7 nodular lymphocyte predominant hodgkin lymphoma 31.0 TNFRSF8 PDCD1 BCL6
8 t-cell lymphoma, subcutaneous panniculitis-like 31.0 TNFRSF8 TIA1 GZMB
9 hodgkin's lymphoma, lymphocytic-histiocytic predominance 30.9 TNFRSF8 BCL6
10 diffuse large b-cell lymphoma 30.9 VEGFA TNFRSF8 SYK PDCD1 MME BCL6
11 panniculitis 30.8 TNFRSF8 TIA1 GZMB
12 primary cutaneous t-cell lymphoma 30.8 TNFRSF8 PDCD1
13 mycosis fungoides 30.8 TNFRSF8 TIA1 GZMB CD28
14 hepatosplenic t-cell lymphoma 30.7 TIA1 GZMB
15 lymphoblastic lymphoma 30.6 TNFRSF8 MME BCL6
16 composite lymphoma 30.6 TNFRSF8 TIA1 MME GZMB BCL6
17 thrombocytopenia 30.6 TBX21 SYK PDCD1 ITK GZMB
18 plasma cell neoplasm 30.6 MME MAF BCL6
19 castleman disease 30.5 VEGFA CXCL13 BCL6
20 mantle cell lymphoma 30.4 VEGFA SYK MME BCL6
21 lymphoma, non-hodgkin, familial 30.4 VEGFA TNFRSF8 SYK MME GZMB CD28
22 burkitt lymphoma 30.3 VAV1 TNFRSF8 MME CXCL13 BCL6
23 hematologic cancer 30.1 VEGFA TNFRSF8 SYK MME BCL6
24 leukemia, chronic lymphocytic 29.6 VEGFA TNFRSF8 TET2 SYK MME ITK
25 leukemia, acute myeloid 29.4 VEGFA VAV1 TNFRSF8 TET2 SYK MME
26 myeloma, multiple 29.2 VEGFA TNFRSF8 MME MAF IDH2 GZMB
27 systemic lupus erythematosus 29.2 VEGFA TBX21 SYK PDCD1 ICOS CXCL13
28 exanthem 10.8
29 splenomegaly 10.7
30 lymphoproliferative syndrome 10.7
31 polyclonal hypergammaglobulinemia 10.7
32 hemolytic anemia 10.7
33 ureteral lymphoma 10.6 MME BCL6
34 bladder lymphoma 10.5 MME BCL6
35 chest wall lymphoma 10.5 MME BCL6
36 prostate lymphoma 10.5 MME BCL6
37 anemia, autoimmune hemolytic 10.5
38 hypereosinophilic syndrome 10.5
39 epiglottis neoplasm 10.5 MME BCL6
40 retroperitoneal lymphoma 10.5 TNFRSF8 MME
41 heart lymphoma 10.5 MME BCL6
42 ovarian lymphoma 10.5 MME BCL6
43 autoimmune disease 10.5
44 intravascular large b-cell lymphoma 10.5 MME BCL6
45 eye lymphoma 10.5 CXCL13 BCL6
46 follicular lymphoma 10.5
47 pure red-cell aplasia 10.5
48 purpura 10.5
49 red cell aplasia 10.5
50 colon lymphoma 10.5 MME BCL6

Graphical network of the top 20 diseases related to Angioimmunoblastic T-Cell Lymphoma:



Diseases related to Angioimmunoblastic T-Cell Lymphoma

Symptoms & Phenotypes for Angioimmunoblastic T-Cell Lymphoma

UMLS symptoms related to Angioimmunoblastic T-Cell Lymphoma:


exanthema

MGI Mouse Phenotypes related to Angioimmunoblastic T-Cell Lymphoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.31 BCL6 CD28 CXCL13 ICOS ITK PDCD1
2 immune system MP:0005387 10.28 BCL6 CD28 CXCL13 ICOS ITK MAF
3 endocrine/exocrine gland MP:0005379 10.25 BCL6 CD28 ICOS ITK PDCD1 PDCD1LG2
4 cellular MP:0005384 10.23 BCL6 CD28 CXCL13 ITK MME PDCD1
5 homeostasis/metabolism MP:0005376 10.18 BCL6 CD28 ICOS MAF MME PDCD1
6 neoplasm MP:0002006 9.81 CD28 ICOS IDH2 PDCD1 PDCD1LG2 RC3H1
7 liver/biliary system MP:0005370 9.8 BCL6 MME PDCD1 RC3H1 SYK TET2
8 no phenotypic analysis MP:0003012 9.5 BCL6 ICOS PDCD1LG2 RC3H1 SYK TET2
9 renal/urinary system MP:0005367 9.17 MAF PDCD1 RC3H1 RHOA SYK TET2

Drugs & Therapeutics for Angioimmunoblastic T-Cell Lymphoma

Drugs for Angioimmunoblastic T-Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 289)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pirarubicin Investigational Phase 4 72496-41-4
2
asparaginase Phase 4
3 Orange Approved Phase 3
4
Cefepime Approved, Investigational Phase 3 88040-23-7 5479537
5
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
6
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
7
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
8
Ondansetron Approved Phase 3 99614-02-5 4595
9
Dalteparin Approved Phase 3 9005-49-6
10
Tinzaparin Approved Phase 3 9041-08-1, 9005-49-6 25244225
11
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
12
Ofloxacin Approved Phase 3 82419-36-1 4583
13
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
14
Darbepoetin alfa Approved, Investigational Phase 3 11096-26-7, 209810-58-2
15
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
16
Iron Approved, Experimental Phase 3 15438-31-0, 7439-89-6 27284 23925
17
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 2826718 468682
18
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
19
Azacitidine Approved, Investigational Phase 3 320-67-2 9444
20
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
21
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
22 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
23 Anesthetics, Dissociative Phase 3
24 Antifungal Agents Phase 3
25 Gastrointestinal Agents Phase 3
26 Antiemetics Phase 3
27 Cola Phase 3
28 Hematinics Phase 3
29 Liver Extracts Phase 3
30 Neurotransmitter Agents Phase 3
31 Analgesics, Opioid Phase 3
32 Psychotropic Drugs Phase 3
33 Anti-Anxiety Agents Phase 3
34 Antipsychotic Agents Phase 3
35 Antiprotozoal Agents Phase 3
36 Antiparasitic Agents Phase 3
37 Analgesics Phase 3
38 Heparin, Low-Molecular-Weight Phase 3
39 Excitatory Amino Acid Antagonists Phase 3
40 Narcotics Phase 3
41 Epoetin alfa Phase 3 113427-24-0
42 Anesthetics Phase 3
43 Anesthetics, General Phase 3
44 Anesthetics, Intravenous Phase 3
45 ferric gluconate Phase 3
46 Iron Supplement Phase 3
47 Amebicides Phase 3
48 Liposomal amphotericin B Phase 3
49
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
50
Arsenic trioxide Approved, Investigational Phase 2 1327-53-3 518740

Interventional clinical trials:

(show top 50) (show all 272)
# Name Status NCT ID Phase Drugs
1 An Open-label,Multicenter Randomised Study of CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for the New Diagnosed Young Patients With T Cell Non-hodgkin Lymphoma Unknown status NCT01746992 Phase 4 Cyclophosphamide 750mg/m2;Vincristine 1.4mg/m2;Doxorubicin 50mg/m2;prednisone 60mg/m2;ifosfamide 2000mg/m2;pirarubicin 50mg/m2;pirarubicin 25mg/m2;Etoposide phosphate 100mg/m2;methotrexate 1500mg/m2
2 Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone (PIGLETS Regimen) as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas (PTCLs) Recruiting NCT03071822 Phase 4 cisplatin;ifosfamide;gemcitabine;L-asparaginase;etoposide;dexamethasone
3 Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients Unknown status NCT03023358 Phase 3 chidamide;cyclophosphamide;liposomal doxorubicin;vincristine;prednisone
4 Phase III Study of CHOP-14 Plus or Minus Alemtuzumab in Peripheral T-cell Lymphoma of the Elderly Unknown status NCT00725231 Phase 3 chemotherapy
5 Randomised Study Comparing 6 And 8 Cycles Of Chemotherapy With CHOP ( Cyclophosphamide, Doxorubicin, Vincristine And Prednisone) At 14-Day Intervals (CHOP-14), Both With Or Without The Monoclonal Anti-CD20 Antibody Rituximab In Patients Aged 61 To 80 Years With Aggressive Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
6 A Prospective Randomised Phase III Trial of Early Hospital Discharge Versus Standard Inpatient Management of Cancer Patients With Low-Risk Febrile Neutropenia Receiving Oral Antibiotics. Oral Antibiotics for Neutropenic Sepsis Giving Early Hospital Discharge [ORANGE] Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
7 Multicenter, Double-Blind, Randomized Study to Compare the Safety and Efficacy of Levofloxacin With That of Cefepime in the Treatment of Fever and Neutropenia - Phase IIIB Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
8 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
9 Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer Completed NCT00006348 Phase 3 ondansetron
10 A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters Completed NCT00006083 Phase 3 Fragmin
11 A Randomized, Prospective Double-Blind, Placebo-Controlled Trial of Prophylactic Oral Levofloxacin Following Chemotherapy for Lymphoma and Solid Tumors Completed NCT00005590 Phase 3 levofloxacin
12 Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia Completed NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
13 A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
14 A Randomized, Open-Label, Multicenter Study Of Darbepoetin Alfa Administered Once Every Two Weeks (Q2W) Compared With rHuEPO Administered Once Every Week (QW) For The Treatment Of Anemia In Subjects With Non-Myeloid Malignancies Receiving Multiple Chemotherapy Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
15 Phase III Study Of Gemcitabine, Dexamethasone, And Cisplatin Compared To Dexamethasone, Cytarabine, And Cisplatin Plus/Minus Rituximab [(R)-GDP vs (R)-DHAP] As Salvage Chemotherapy For Patients With Relapsed Or Refractory Aggressive Histology Non-Hodgkin's Lymphoma Prior To Autologous Stem Cell Transplant And Followed By Maintenance Rituximab vs Observation Completed NCT00078949 Phase 3 cisplatin;cytarabine;dexamethasone;gemcitabine hydrochloride
16 Does Hypericum Reduce Fatigue in Cancer Patients on Chemotherapy? A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Completed NCT00005805 Phase 3
17 A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Cancer Patients With Chemotherapy-Associated Anemia Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
18 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
19 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
20 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
21 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
22 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
23 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
24 Randomized Phase 3 Study Evaluating the Efficacy and the Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patient With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma Recruiting NCT03593018 Phase 3 Oral azacitidine;Romidepsin;Bendamustine;Gemcitabine
25 Randomized Phase 3 Study Evaluation the Efficacy and Safety of Oral Azacitidine(CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma Recruiting NCT03703375 Phase 3 Azacitidine;Romidepsin;Gemcitabine
26 CELTIC-1 (Clinical Evaluation of T-cell NHL With Cerdulatinib): A Phase 2b, Open Label, Multidose, Multinational Study of Cerdulatinib (PRT062070) in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) Withdrawn NCT04021082 Phase 2, Phase 3 Cerdulatinib
27 Chidamide With PET Regimen for Angioimmunoblastic T Cell Lymphoma, a Multicentric, Single Arm, Open Label Phase II Clinical Trial Unknown status NCT03273452 Phase 2 Chidamide
28 Phase II Trial of Fludarabine & Cyclophosphamide Followed by Thalidomide for Angioimmunoblastic Lymphoma Unknown status NCT00958854 Phase 2 cyclophosphamide;fludarabine phosphate;thalidomide
29 Chimeric Antigen Receptor-Modified pNK Cells for CD7 Positive Relapsed or Refractory Leukemia and Lymphoma Unknown status NCT02742727 Phase 1, Phase 2
30 Alemtuzumab and CHOP Chemotherapy for Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Centre Phase I and II Study Unknown status NCT00363090 Phase 1, Phase 2 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
31 Allograft of Hematopoietic Stem Cells With Reduced-intensity Conditioning From a HLA-haploidentical Family Donor: Phase II Study of Combined Immunosuppression Before and After Transplantation Unknown status NCT00740467 Phase 2 busulfan;cyclophosphamide;cyclosporine;fludarabine phosphate;mycophenolate mofetil
32 Non-Ablative Chemotherapeutic Conditioning Before Allogeneic Stem Cell Transplantation Unknown status NCT00008307 Phase 2 cyclosporine;fludarabine phosphate;melphalan;methylprednisolone;mycophenolate mofetil
33 Phase 2 Study of Endostar Combined With CHOP Regimen as the First Line Chemotherapy for Untreated Peripheral T Cell Lymphoma Unknown status NCT00974324 Phase 2 endostar and CHOP
34 A Phase 1/2, Multicenter, Open-Label, Dose-Escalation Study of AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, That Harbor an IDH2 Mutation Completed NCT02273739 Phase 1, Phase 2 AG-221
35 STUDY OF THE EFFICACY AND SAFETY OF FIRST LINE TREATMENT WITH CHOP AND LENALIDOMIDE (Rev-CHOP) IN PATIENTS AGED FROM 60 TO 80 YEARS WITH PREVIOUSLY UNTREATED ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL) Completed NCT01553786 Phase 2 Lenalidomide
36 A Phase II Study of Oxaliplatin in Relapsed and Refractory Non-Hodgkin's Lymphoma Completed NCT00006473 Phase 2 oxaliplatin
37 A Phase II Study of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) Alternating With Pralatrexate (P) as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin Lymphoma Completed NCT01336933 Phase 2 prednisone;cyclophosphamide;etoposide;Vincristine;pralatrexate
38 A Phase II Trial of Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell Lymphoma: BENCART Trial Completed NCT02424045 Phase 2 BCD chemotherapy (Bendamustine, Carboplatin, Dexamethasone)
39 Phase II Study of Arsenic Trioxide (NSC #706363) in Relapsed and Refractory Intermediate and High-Grade Non-Hodgkin's Lymphoma Completed NCT00005040 Phase 2 arsenic trioxide
40 Phase II Trial of Everolimus (RAD001) in Relapsed/Refractory Lymphoma Completed NCT00436618 Phase 2 Everolimus
41 Gem-CHOP: A Randomized Phase II Study of Gemcitabine Combined With CHOP in Untreated Aggressive Non-Hodgkin's Lymphoma Completed NCT00079261 Phase 2 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;gemcitabine hydrochloride;prednisone;vincristine sulfate
42 A Phase 1/2a Open-label Study of Pralatrexate and Gemcitabine With Vitamin B12 and Folic Acid Supplementation in Patients With Relapsed or Refractory Lymphoproliferative Malignancies Completed NCT00481871 Phase 1, Phase 2 Pralatrexate Injection;Gemcitabine Hydrochloride
43 Diffuse Large B Cell And Peripheral T-Cell Non-Hodgkin's Lymphoma In The Frail Elderly. Progressive And Cautious Treatment Strategy In Poor Status Patients. A Phase II Trial With Emphasis On Geriatric Assessment And Quality Of Life Completed NCT00039351 Phase 2 cyclophosphamide;prednisone;vincristine sulfate
44 OUTPATIENT SUBCUTANEOUS IL-2 AND ALPHA INTERFERON IN THE MANAGEMENT OF METASTATIC CANCER Completed NCT00002504 Phase 2
45 An Open-Label, Intravenous To Oral Switch, Multiple Dose, Multi-Center Study To Investigate The Pharmacokinetics, Safety And Tolerability Of Voriconazole In Hospitalized Children Aged 2 - <12 Years Who Require Treatment For The Prevention Of Systemic Fungal Infection Completed NCT00066599 Phase 2 voriconazole
46 Study of the Efficacy and the Safety of First Line Treatment With CHOP Plus Rituximab (R-CHOP) in Patients Aged 60 to 80 Years With Previously Untreated T-cell Angioimmunoblastic Lymphoma (AIL). Completed NCT00169156 Phase 2 Rituximab;Prednisone;Doxorubicine;Cyclophosphamide;Vincristine
47 A Phase II Study of 506U78 in Patients With Previously Systemically Untreated Cutaneous T-cell Lymphoma (CTCL) or With Refractory or Relapsed Non-cutaneous Peripheral T-cell Lymphoma (PTCL) Completed NCT00005080 Phase 2 nelarabine
48 Donor NK Cell Infusion for Progression/Recurrence of Underlying Malignant Disorders After HLA-haploidentical HCT - a Phase 1-2 Study Completed NCT00823524 Phase 1, Phase 2
49 Purine-Analog-Containing Non-Myeloablative Allogeneic Stem Cell Transplantation for Treatment of Hematologic Malignancies and Severe Aplastic Anemia Completed NCT00006379 Phase 2 cyclophosphamide;fludarabine phosphate
50 Ex Vivo Expanded Megakaryocytes for Supportive Care of Breast Cancer Patients: A Phase I/II Study Completed NCT00006225 Phase 1, Phase 2

Search NIH Clinical Center for Angioimmunoblastic T-Cell Lymphoma

Cochrane evidence based reviews: immunoblastic lymphadenopathy

Genetic Tests for Angioimmunoblastic T-Cell Lymphoma

Anatomical Context for Angioimmunoblastic T-Cell Lymphoma

MalaCards organs/tissues related to Angioimmunoblastic T-Cell Lymphoma:

40
T Cells, B Cells, Bone, Bone Marrow, Lymph Node, Nk Cells, Endothelial

Publications for Angioimmunoblastic T-Cell Lymphoma

Articles related to Angioimmunoblastic T-Cell Lymphoma:

(show top 50) (show all 1163)
# Title Authors PMID Year
1
Identification of CXCL13 as a new marker for follicular dendritic cell sarcoma. 54 61
18792075 2008
2
Expression of CXCL13, a chemokine highly upregulated in germinal center T-helper cells, distinguishes angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified. 61 54
16680156 2006
3
Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL): a new diagnostic marker providing evidence that AITL derives from follicular helper T cells. 61 54
16625095 2006
4
CD10 and BCL6 expression in the diagnosis of angioimmunoblastic T-cell lymphoma: utility of detecting CD10+ T cells by flow cytometry. 61 54
16084948 2005
5
Molecular-cytogenetic characterization of non-Hodgkin's lymphoma with double and cryptic translocations of the immunoglobulin heavy chain gene. 61 54
15370207 2004
6
Rare non-Hodgkin lymphoma of childhood and adolescence: A consensus diagnostic and therapeutic approach to pediatric-type follicular lymphoma, marginal zone lymphoma, and nonanaplastic peripheral T-cell lymphoma. 61
32452165 2020
7
Effects of stem cell transplantation in patients with peripheral T-cell lymphoma not otherwise specified and angioimmunoblastic T-cell lymphoma. 61
32297159 2020
8
Multiple mutations at exon 2 of RHOA detected in plasma from patients with peripheral T-cell lymphoma. 61
32484856 2020
9
Efficacy and safety of single-agent pralatrexate for treatment of angioimmunoblastic T-cell lymphoma after failure of first line therapy: a pooled analysis. 61
32536233 2020
10
Improving survival of 3760 patients with lymphoma: Experience of an academic center over two decades. 61
32281275 2020
11
[Neutrophil-Lymphocyte Ratio as a Prognostic Predictor in Patients with Newly Diagnosed Angioimmunoblastic T Cell Lymphoma]. 61
32552949 2020
12
Unique evolution of angioimmunoblastic T cell lymphoma to Epstein-Barr virus-positive plasma cell myeloma. 61
32514627 2020
13
The derived neutrophil-to-lymphocyte ratio is an independent prognostic factor in patients with angioimmunoblastic T-cell lymphoma. 61
32103494 2020
14
Clonal hematopoiesis in angioimmunoblastic T-cell lymphoma with divergent evolution to myeloid neoplasms. 61
32442302 2020
15
Bone Marrow Infiltration of Angioimmunoblastic T-Cell Lymphoma: Identification and Prognostic Impact of Histologic Patterns and Diagnostic Application of Ancillary Phenotypic and Molecular Analyses. 61
31556696 2020
16
Angioimmunoblastic T-cell lymphoma in Taiwan reveals worse progression-free survival for RHOA G17V mutated subtype. 61
31870198 2020
17
The first report of colonic involvement of angioimmunoblastic T-cell lymphoma. 61
32519962 2020
18
Leukaemic relapse of angioimmunoblastic T-cell lymphoma. 61
32037513 2020
19
Dasatinib Is an Effective Treatment for Angioimmunoblastic T-cell Lymphoma. 61
32107212 2020
20
A Suggested Immunohistochemical Algorithm for the Classification of T Cell Lymphomas Involving Lymph Node. 61
32479842 2020
21
Hypereosinophilia with angioimmunoblastic T-cell lymphoma. 61
32044452 2020
22
Combination of multicolor flow cytometry for circulating lymphoma cells and tests for the RHOAG17V and IDH2R172 hot-spot mutations in plasma cell-free DNA as liquid biopsy for the diagnosis of angioimmunoblastic T-cell lymphoma. 61
32476550 2020
23
Circulating angioimmunoblastic T-cell lymphoma cells. 61
32353128 2020
24
The new biology of PTCL-NOS and AITL: current status and future clinical impact. 61
32064593 2020
25
RELINF: prospective epidemiological registry of lymphoid neoplasms in Spain. A project from the GELTAMO group. 61
32076827 2020
26
Application of NanoString technologies in angioimmunoblastic T cell lymphoma. 61
32146712 2020
27
Characterizing the belinostat response in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma. 61
32336176 2020
28
Diagnostic Dilemma: An Unusual Case of Angioimmunoblastic T-Cell Lymphoma Manifesting as Bone Marrow Non-Caseating Granuloma. 61
32362985 2020
29
Angioimmunoblastic T-cell lymphoma contains multiple clonal T-cell populations derived from a common TET2 mutant progenitor cell. 61
31859368 2020
30
Linear IgA dermatosis in association with angioimmunoblastic T-cell lymphoma infiltrating the skin: A case report with literature review. 61
31482600 2020
31
Progression of AITL-like tumors in mice is driven by Tfh signature proteins and T-B cross talk. 61
32130407 2020
32
Clinicopathological features of programmed cell death-1 and programmed cell death-ligand-1 expression in the tumor cells and tumor microenvironment of angioimmunoblastic T cell lymphoma and peripheral T cell lymphoma not otherwise specified. 61
32170448 2020
33
Immunophenotyping of the PD-L1-positive cells in angioimmunoblastic T cell lymphoma and Hodgkin disease. 61
32143684 2020
34
Bright PD-1 expression by flow cytometry is a powerful tool for diagnosis and monitoring of angioimmunoblastic T-cell lymphoma. 61
32144240 2020
35
The life and death of the germinal center. 61
31751845 2020
36
Clinical analysis of 20 patients with non-Hodgkin lymphoma and autoimmune hemolytic anemia: A retrospective study. 61
32049797 2020
37
Angioimmunoblastic T-cell Lymphoma: An Unusual Case in an Octogenarian. 61
32190506 2020
38
The efficacy and safety of Epstein-Barr virus-specific antigen peptide-activated cytotoxic T-cells treatment for refractory or recurrent angioimmunoblastic T-cell lymphoma: A prospective clinical observational study. 61
32083758 2020
39
Erratum to Inactivation of FOXO1 induces T follicular cell polarization and involves angioimmunoblastic T cell lymphoma. 61
32296592 2020
40
Relapsed angioimmunoblastic T-cell lymphoma with large pericardial effusion. 61
32063773 2020
41
EBV status has prognostic implication among young patients with angioimmunoblastic T-cell lymphoma. 61
31793218 2020
42
Neoantigen-activated haploidentical T cell therapy for angioimmunoblastic T-cell lymphoma. 61
31689517 2020
43
Case Report: Pure Red Cell Aplasia due to Angioimmunoblastic T-Cell Lymphoma. 61
32110223 2020
44
Outcomes of GDPT (gemcitabine, cisplatin, prednisone, thalidomide) versus CHOP in newly diagnosed peripheral T-cell lymphoma patients. 61
32550864 2020
45
Approach to nodal-based T-cell lymphomas. 61
31785821 2020
46
[Leucovorin Administration Allows Continued Pralatrexate Treatment in a Patient with Angioimmunoblastic T-Cell Lymphoma]. 61
32381871 2020
47
Update on peripheral T-cell lymphomas with T-helper phenotype:  Are there too many subtypes? 61
31870687 2020
48
Non-mycosis fungoides cutaneous lymphomas in a referral center in Taiwan: A retrospective case series and literature review. 61
31978091 2020
49
[Angioimmunoblastic T-cell lymphoma complicated with various autoimmune abnormalities and myelofibrosis]. 61
32147609 2020
50
The development of T-cell malignancies in patients with pre-existing myeloproliferative neoplasms: a report of three cases. 61
32256694 2020

Variations for Angioimmunoblastic T-Cell Lymphoma

Cosmic variations for Angioimmunoblastic T-Cell Lymphoma:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM108378711 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.50G>T p.G17V 3:49375540-49375540 0

Expression for Angioimmunoblastic T-Cell Lymphoma

Search GEO for disease gene expression data for Angioimmunoblastic T-Cell Lymphoma.

Pathways for Angioimmunoblastic T-Cell Lymphoma

Pathways related to Angioimmunoblastic T-Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.8 VEGFA VAV1 TNFRSF8 SYK RHOA PDCD1LG2
2
Show member pathways
13.31 VAV1 SYK PDCD1LG2 PDCD1 ITK ICOS
3
Show member pathways
13.25 VAV1 TNFRSF8 SYK RHOA ITK CXCL13
4
Show member pathways
12.66 VEGFA ICOS GZMB CXCL13 CD28
5
Show member pathways
12.45 VAV1 SYK ITK ICOS CD28
6
Show member pathways
12.41 VEGFA VAV1 SYK ITK BCL6
7
Show member pathways
12.26 VAV1 SYK CD28 BCL6
8
Show member pathways
12.17 VAV1 RHOA PDCD1 ITK ICOS CD28
9
Show member pathways
12.1 VEGFA VAV1 SYK RHOA GZMB
10
Show member pathways
12.03 VAV1 SYK ITK ICOS CD28
11 11.93 PDCD1LG2 PDCD1 ICOS CD28
12 11.84 TNFRSF8 TBX21 SYK PDCD1LG2 PDCD1 ITK
13
Show member pathways
11.8 PDCD1LG2 PDCD1 ITK
14
Show member pathways
11.79 VAV1 ITK CD28
15
Show member pathways
11.77 VAV1 SYK ITK
16 11.59 TBX21 ICOS GZMB
17
Show member pathways
11.59 VAV1 PDCD1LG2 PDCD1 ICOS CD28
18 11.19 VAV1 RHOA ITK
19 11.04 PDCD1 ITK CD28
20 10.85 VAV1 SYK
21
Show member pathways
10.66 TET2 IDH2

GO Terms for Angioimmunoblastic T-Cell Lymphoma

Biological processes related to Angioimmunoblastic T-Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.95 VAV1 PDCD1LG2 ICOS CXCL13 CD28
2 immune system process GO:0002376 9.91 SYK PDCD1LG2 PDCD1 ITK CD28 BCL6
3 cell surface receptor signaling pathway GO:0007166 9.88 SYK PDCD1LG2 CXCL13 CD28
4 neutrophil chemotaxis GO:0030593 9.71 VAV1 SYK CXCL13
5 negative regulation of activated T cell proliferation GO:0046007 9.57 RC3H1 PDCD1LG2
6 regulation of T cell proliferation GO:0042129 9.56 RC3H1 CD28
7 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.54 VEGFA VAV1 RHOA
8 positive regulation of cellular component movement GO:0051272 9.52 VEGFA BCL6
9 positive regulation of isotype switching to IgG isotypes GO:0048304 9.51 TBX21 CD28
10 positive regulation of cell adhesion GO:0045785 9.5 VEGFA VAV1 RHOA
11 positive regulation of alpha-beta T cell differentiation GO:0046638 9.49 SYK RHOA
12 negative regulation of T-helper 17 cell differentiation GO:2000320 9.48 TBX21 RC3H1
13 positive regulation of alpha-beta T cell proliferation GO:0046641 9.46 SYK CD28
14 T cell activation GO:0042110 9.43 VAV1 ITK CD28
15 germinal center formation GO:0002467 9.4 CXCL13 BCL6
16 regulation of germinal center formation GO:0002634 9.16 RC3H1 BCL6
17 T cell costimulation GO:0031295 9.02 VAV1 PDCD1LG2 PDCD1 ICOS CD28
18 beta selection GO:0043366 8.96 SYK RHOA

Molecular functions related to Angioimmunoblastic T-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.58 VEGFA VAV1 TNFRSF8 TIA1 TET2 TBX21

Sources for Angioimmunoblastic T-Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....